Pfizer’s blockbuster safety issue jumps the Atlantic as EMA launches its own review of Xeljanz
Pfizer’s Xeljanz woes have spread to Europe.
After the FDA announced earlier this week that it is investigating the increased risk of blood clots …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
